Psoriasis treatment and management - a systematic review of full economic evaluations

Hamilton, Matthew; Ntais, Dionysios; Griffiths, C.E.M.; Davies, Linda

doi:10.1111/bjd.13486

Cited by 15 publications

(18 citation statements)

References 60 publications

(501 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 43 However, cost estimates for all biologics vary widely in the literature, and are accompanied by high levels of uncertainty. 44 , 45 Further research is needed to evaluate the cost-effectiveness of all biologics for psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Yang¹,

Beck²,

Liao³

2018

PTT

View full text Add to dashboard Cite

Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Yang¹,

Beck²,

Liao³

2018

PTT

View full text Add to dashboard Cite

show abstract

“…Psoriasis, a chronic, inflammatory and immune‐mediated disease affecting the skin, has been related to cardiovascular disease owing to enhanced systemic inflammation and resulting atherosclerosis . Adults and people living in countries further from the equator are more common to suffer from psoriasis, and presently, no cure for psoriasis has been discovered; therefore, psoriatic patients frequently need lifetime management . In the past decade, some treatment guidelines, tools, and standards have been introduced and applied, especially in European countries .…”

Section: Introductionmentioning

confidence: 99%

Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway

Chen

Fan

Wang

et al. 2019

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Psoriasis is a multisystem disease affecting about 2% of the population, while keratin16 (KRT16) has been reported to participate in psoriasis. However, the specific mechanism of KRT16 in psoriasis was inadequately investigated. The objective of the study was to elucidate the mechanism by which siRNA‐mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal‐related kinase (ERK) signaling pathway. Psoriasis‐related core gene KRT16 was screened out. Then, the expression of KRT16, VEGF, and ERK signaling pathway‐related genes was detected in psoriatic patients. To further investigate the mechanism of KRT16, keratinocytes in psoriatic patients were treated with KRT16 siRNA or/and ERK inhibitor (PD98059) to detect the changes in related gene expression and cell survival. KRT16 was involved in psoriasis development. The expression levels of KRT16, p‐ERK1/2, and VEGF in lesion tissues are significantly elevated. Keratinocytes treated with KRT16‐siRNA and KRT16‐siRNA + PD98059 exhibited reduced KRT16, p‐ERK1/2, and VEGF expression. The cell survival rate in cells treated with KRT16‐siRNA, PD98059, and KRT16‐siRNA + PD98059 reduced significantly. These findings indicate that silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway, which provides a basic theory in the treatment of psoriasis.

show abstract

“…Emollients, topical corticosteroids, vitamin D analogs, calcipotriene, calcitriol, tazarotene, calcineurin inhibitors, anthralin, narrowband ultraviolet B (UVB), methotrexate, apremilast and biological agents are the treatment options for psoriasis depending on the severity of the disease (9). However, no curative treatment has yet been discovered (9).…”

Section: Introductionmentioning

confidence: 99%

Psoriasis and Pregnancy: Retrospective Evaluation of 47 Pregnancies in a Tertiary Center

Tanacan

Fadıloğlu

Ünal

et al. 2019

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

Objective: To evaluate the impact of psoriasis on pregnancy outcomes.Study Design: Data of pregnant women with chronic plaque psoriasis who were followed up at Hacettepe University Hospital between January 1, 2010 and December 31, 2017 were evaluated. Pregnant women with singleton pregnancies who had chronic plaque psoriasis were included in the study. Patients were divided into two groups based on the clinical course of psoriasis: group 1 (improvement/disease-stable), and group 2 (deterioration). Median maternal age, gravida, parity, gestational week at birth, birthweight, 5th minute APGAR score together with the rates of cesarean section, neonatal intensive care unit admission and pregnancy complications (spontaneous abortion, preterm delivery, fetal growth restriction and preeclampsia) were compared between the groups.Results: There were 29 (61.7%) patients in group 1 and 18 (38.3%) patients in group 2. Mean values for maternal age, gravida and parity were comparable between the groups (p values were 0.32, 0.09 and 0.17, respectively). Median values for gestational week at birth (39.2 vs 36.1, p =0.002), birthweight (3200 vs 2310, p =0.002) and 5th minute APGAR score (9 vs 7, p <0.001) were statistically significantly lower in group 2. Cesarean section (33.3% vs 71.4%, p =0.02), neonatal intensive care unit admission (11.1% vs 64.3%, p <0.001) and pregnancy complication rates (p =0.003) were statistically significantly higher in group 2. Frequencies of spontaneous abortion, preterm delivery, fetal growth restriction and preeclampsia were 6.9%, 10.3%, 3.4% and 3.4% in group 1, and 22.2%, 27.8%, 16.7% and 16.7% in group 2, respectively.Conclusion: Deterioration of psoriasis in pregnancy was associated with adverse obstetric outcome.

show abstract

Psoriasis treatment and management - a systematic review of full economic evaluations

Cited by 15 publications

References 60 publications

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway

Psoriasis and Pregnancy: Retrospective Evaluation of 47 Pregnancies in a Tertiary Center

Contact Info

Product

Resources

About